샘플 요청 목록

 카트 문의
시장보고서
상품코드
1733483

세계의 당뇨병성 위마비 치료 시장

Diabetic Gastroparesis Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 368 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

당뇨병성 위마비 치료 세계 시장은 2030년까지 27억 달러에 도달

2024년에 23억 달러로 추정되는 당뇨병성 위마비 치료 세계 시장은 2024-2030년간 CAGR 2.6%로 성장하여 2030년에는 27억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 의약품은 CAGR 3.3%를 나타내고, 분석 기간 종료시에는 17억 달러에 이를 것으로 예측됩니다. 외과 치료 제품 부문의 성장률은 분석 기간중 CAGR 1.6%로 추정됩니다.

미국 시장은 6억 2,220만 달러로 추정, 중국은 CAGR 5.2%로 성장 예측

미국의 당뇨병성 위마비 치료 시장은 2024년에는 6억 2,220만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 5.2%로서 2030년까지 5억 1,970만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.0%와 2.1%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.4%로 전망됩니다.

세계의 당뇨병성 위마비 치료 시장-주요 동향과 촉진요인 정리

치료 혁신이 미진단 질환을 따라잡을 수 있을까?

당뇨병성 위부전마비(장기적인 당뇨병으로 인한 만성적인 위 운동 장애)는 당뇨병의 합병증 중 가장 진단이 늦고 치료가 어려운 질환 중 하나입니다. 당뇨병성 위부전마비는 주로 1형 당뇨병과 장기간 지속된 2형 당뇨병에서 발생하며, 위배출 지연, 메스꺼움, 구토, 복부 팽만감, 혈당 조절 장애를 유발합니다. 현재 전 세계 당뇨병성 위부전 마비 치료 시장은 질환에 대한 인식 증가, 진단의 개선, 새로운 프로키네틱 요법의 도입 등으로 인해 변화의 시기를 맞이하고 있습니다.

가장 중요한 트렌드 중 하나는 대증요법에서 표적 운동기능 조절제로의 전환입니다. 과거에는 식이요법, 구토억제제, 적응증 외 운동촉진제의 사용으로 대처해왔으나, 현재는 선택적 세로토닌 수용체 작용제, 그렐린 수용체 작용제, CGRP 길항제에 초점을 맞춘 의약품의 연구개발이 활발히 진행되고 있습니다. 이러한 기술 혁신은 단순히 증상을 억제하는 것이 아니라 위 운동 장애의 근본적인 병태생리를 다루는 것을 목표로 하고 있습니다.

연구 개발은 위마비 치료 상황을 어떻게 재구성하고 있는가?

기존의 치료법은 오랫동안 메토클로프라미드, 돈페리돈, 에리스로마이신, 온단세트론에 의존해 왔습니다. 그러나 이들 약제는 원추체외로 증상, QT 연장, 빈맥 등의 부작용으로 인해 장기간 사용이 제한되어 왔습니다. 이에 따라 제약사들은 보다 타겟을 좁히고더 잘 견딜 수 있는 프로키네틱 약물의개발을 진행하고 있습니다. 유망한 후보물질로는 위 배출을 촉진하고 중추신경계 부작용이 적고 증상의 중증도를 감소시킬 수 있는 가능성을 보이는 그렐린 수용체 작용제인relamorelin이있습니다.

기타 임상시험 중인 약물로는 velusetrag(5-HT4 작용제)) 및camicinal이모두 심혈관계나 신경계의 위험 없이 소화관 운동을 선택적으로 자극할 수 있도록 고안되었습니다. 또한, 유문괄약근에 보툴리눔툭신(보톡스) 주사나 위 전기 자극도 난치성 환자들을 위한 중재적 치료 옵션으로 검토되고 있습니다. 이러한 발전으로, 특히 증상이 심하고 위 신티그래피 검사에서 위 배출 지연이 확인된 환자들에게 개별화된메커니즘에 기반한 치료법으로초점이 이동하고 있습니다.

수요는 어디에서 발생하며, 주요 이해관계자는 누구인가?

당뇨병성 위부전 마비 치료 시장은 당뇨병 유병률이 높은 지역, 특히 북미, 서유럽, 중국, 인도에 집중되어 있습니다. 미국은 운동기능 검사 및 전문 소화기내과 서비스에 대한 접근성이 좋아 진단율과 치료 보급률 모두에서 시장을 선도하고 있습니다. 그러나 증상이 다른 소화기 질환과 중복되는 경우가 많고, 표준화된 평가 프로토콜이 없어 진단 부족이 전 세계적으로 큰 걸림돌로 작용하고 있습니다.

내분비내과 전문의, 소화기내과 전문의, 당뇨병 전문의는 중요한 처방자이며, 치료 결정에는 다학제적 협력이 필요한 경우가 많습니다. 중증 환자의 진단과 관리에 있어 대학병원과 3차 의뢰 병원이 중요한 역할을 하는 한편, 제약사들은 이들 기관과 긴밀하게 협력하여 임상시험을 진행하며 치료 적응증을 확대하고 있습니다. 또한, 당뇨병 환자 지원 단체와 원격 의료 플랫폼은 증상을 조기에 발견하고 치료 접근성과 순응도를 향상시키는 데 기여하고 있습니다.

당뇨병성 위마비 치료제 시장의 성장을 주도하는 요인은?

당뇨병성 위부전 마비 치료제 시장의 성장은 당뇨병 유병률, 미충족 의료 수요, 새로운 약리학적 솔루션과 관련된 몇 가지 요인에 의해 주도되고 있습니다. 전 세계적으로 당뇨병 환자가 증가함에 따라(특히 젊은 연령층과 고령화) 위부전 마비 잠재 환자군이 크게 확대되고 있으며, 특히 잘 관리되지 않거나 인슐린에 의존하는 환자에서 두드러지게 나타나고 있습니다. 위 운동 기능 진단 약품에 대한 인식과 접근성이 향상됨에 따라 다른 소화기 질환과의 감별 및 검출이 향상되고 있습니다.

의약품의 기술 혁신이 주요 촉진요인이며, 새로운 유형의 프로키네틱스와 증상 표적 치료제가 후기 임상 단계에 진입하고 있습니다. 이러한 약물은 내약성과 효능이 개선되어 이전에는 적응증 외의 부작용이 발생하기 쉬운 치료법이 주류를 이루었던 이 분야에서 보다 안전한 장기적 해결책으로 자리매김하고 있습니다. 또한, 진단 검사 및 전문 진료에 대한 의료보험 적용 범위가 개선된 것도 선진국에서 시장 침투를 촉진하고 있습니다.

원격 증상 추적 앱, 웨어러블 혈당 측정기, AI 기반 식단 관리 플랫폼 등 디지털 헬스 툴의 통합은 보다 개인화된 치료 계획을 촉진하고 있습니다. 이러한 기술 통합과 더불어, 표적화된 교육 캠페인 및 임상시험의 확대는 전 세계 의료 시스템 전반에서 당뇨병성 위마비를 이해하고, 관리하고, 수익을 창출하는 방법을 재구성하고 있습니다.

부문

제품 유형(의약품, 외과적 치료 제품);질환 적응(대상성 위부전증, 위부전);판매채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 예(주요 41개사)

  • Abbott Laboratories
  • AbbVie Inc.
  • Alfa Wassermann S.p.A.
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • C. R. Bard, Inc.(BD)
  • Cardinal Health, Inc.
  • Cipla Limited
  • Evoke Pharma, Inc.
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • Medtronic plc
  • Neurogastrx, Inc.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vanda Pharmaceuticals, Inc.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

무료 업데이트 각국의 최종 리셋이 발표된 후, 7월에 무료 업데이트 버전을 고객님들께 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국의 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.10

Global Diabetic Gastroparesis Treatment Market to Reach US$2.7 Billion by 2030

The global market for Diabetic Gastroparesis Treatment estimated at US$2.3 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Surgical Treatment Products segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$622.2 Million While China is Forecast to Grow at 5.2% CAGR

The Diabetic Gastroparesis Treatment market in the U.S. is estimated at US$622.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$519.7 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Diabetic Gastroparesis Treatment Market - Key Trends & Drivers Summarized

Is Therapeutic Innovation Catching Up With an Underdiagnosed Condition?

Diabetic gastroparesis-a chronic gastric motility disorder caused by long-term diabetes-remains one of the most underdiagnosed and difficult-to-treat complications of diabetes. It primarily affects individuals with Type 1 and long-standing Type 2 diabetes, leading to delayed gastric emptying, nausea, vomiting, bloating, and impaired glycemic control. The global diabetic gastroparesis treatment market is now undergoing a transformation, driven by growing disease awareness, diagnostic improvements, and the introduction of novel prokinetic therapies.

One of the most significant trends is the transition from symptomatic treatment to targeted motility-modulating agents. Historically managed with dietary modifications, antiemetics, and off-label use of prokinetics, the market is now witnessing a resurgence in pharmaceutical R&D focused on selective serotonin receptor agonists, ghrelin receptor agonists, and CGRP antagonists. These innovations aim to address the underlying pathophysiology of impaired gastric motility rather than merely suppress symptoms.

How Is R&D Reshaping the Therapeutic Landscape for Gastroparesis?

Traditional treatment approaches have long relied on metoclopramide, domperidone, erythromycin, and ondansetron. However, their long-term use is limited by adverse effects such as extrapyramidal symptoms, QT prolongation, and tachyphylaxis. In response, pharmaceutical companies are developing more targeted, better-tolerated prokinetic agents. Promising candidates include relamorelin, a ghrelin receptor agonist that enhances gastric emptying and shows potential in reducing symptom severity with fewer CNS side effects.

Other drugs in clinical trials include velusetrag (5-HT4 agonist) and camicinal, both designed to selectively stimulate gastrointestinal motility without cardiovascular or neurological risks. Additionally, botulinum toxin injections into the pyloric sphincter and gastric electrical stimulation are being explored as interventional options for refractory cases. These advancements are shifting the focus toward personalized, mechanism-based therapies, particularly for patients with severe symptoms and delayed gastric emptying confirmed by gastric scintigraphy.

Where Is Demand Emerging and Who Are the Primary Stakeholders?

The diabetic gastroparesis treatment market is concentrated in regions with high diabetes prevalence-particularly in North America, Western Europe, China, and India. The U.S. leads the market in terms of both diagnosis rates and treatment adoption due to greater access to motility testing and specialized gastroenterology services. However, underdiagnosis remains a major hurdle globally, as symptoms often overlap with other gastrointestinal conditions and lack standardized evaluation protocols.

Endocrinologists, gastroenterologists, and diabetologists are key prescribers, with treatment decisions often requiring multidisciplinary coordination. Academic medical centers and tertiary referral hospitals play a crucial role in diagnosing and managing severe cases, while pharmaceutical companies are working closely with these institutions to conduct clinical trials and expand therapeutic indications. Moreover, diabetic patient advocacy groups and telemedicine platforms are contributing to earlier recognition of symptoms, thereby improving treatment access and adherence.

What’s Driving Growth in the Diabetic Gastroparesis Treatment Market?

The growth in the diabetic gastroparesis treatment market is driven by several factors tied to diabetes incidence, unmet clinical need, and emerging pharmacological solutions. The global rise in diabetes-particularly in younger adults and the aging population-has significantly expanded the potential patient pool for gastroparesis, especially in poorly managed or insulin-dependent cases. Increasing awareness and availability of gastric motility diagnostics are also improving detection and differentiation from other GI disorders.

Pharmaceutical innovation is a key growth driver, with new classes of prokinetics and symptom-targeted therapies entering late-stage clinical development. These agents offer improved tolerability and efficacy, positioning them as safer long-term solutions in a field previously dominated by off-label and side-effect-prone treatments. Additionally, improvements in health insurance coverage for diagnostic tests and specialty consultations are aiding market penetration in developed countries.

The convergence of digital health tools-including remote symptom tracking apps, wearable glycemic monitors, and AI-assisted dietary management platforms-is also fostering more individualized treatment plans. These technological integrations, along with targeted education campaigns and expanding clinical trials, are reshaping how diabetic gastroparesis is understood, managed, and monetized across global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Diabetic Gastroparesis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Drugs, Surgical Treatment Products); Disease Indication (Compensated Gastroparesis, Gastric Failure); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Abbott Laboratories
  • AbbVie Inc.
  • Alfa Wassermann S.p.A.
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • C. R. Bard, Inc. (BD)
  • Cardinal Health, Inc.
  • Cipla Limited
  • Evoke Pharma, Inc.
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • Medtronic plc
  • Neurogastrx, Inc.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vanda Pharmaceuticals, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Diabetic Gastroparesis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Type 1 and Type 2 Diabetes Propels Demand for Gastroparesis Therapies
    • Increased Awareness and Diagnosis Rates Throw the Spotlight on Unmet Clinical Needs in Gastroparesis Management
    • Launch of Novel Prokinetic Agents Strengthens Business Case for Pharmacological Intervention
    • Advancements in Gastric Electrical Stimulation Devices Accelerate Innovation in Non-Pharmacological Treatments
    • Regulatory Approvals for New Drug Classes Drive Competitive Landscape in Diabetic Gastroparesis Treatment
    • Patient-Centric Care Models Propel Growth in Personalized Gastroparesis Treatment Strategies
    • Rising Healthcare Expenditure in Emerging Markets Expands Access to Advanced Therapeutics
    • Growing Pipeline of Promotility Agents Spurs Market Interest Among Biopharma Investors
    • Post-Pandemic Focus on Gastrointestinal Complications in Diabetics Drives Disease Monitoring and Therapy Uptake
    • Clinical Research Linking Gastroparesis to Poor Glycemic Control Highlights Need for Targeted Treatment
    • Integration of Digital Health Monitoring Tools Enhances Early Detection and Treatment Adherence
    • Increased Hospitalization Due to Gastroparesis Complications Generates Urgency for Effective Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Diabetic Gastroparesis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Surgical Treatment Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Surgical Treatment Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Surgical Treatment Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Compensated Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Compensated Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Compensated Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gastric Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gastric Failure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제